Navigation Links
Exelixis Announces Third Quarter 2007 Financial Results and Business Update
Date:11/5/2007

ible assets 51 210 195 722

Total operating

expenses 69,451 55,101 198,505 161,900

Loss from operations (42,626) (31,561) (114,285) (93,001)

Other income (expense):

Interest income and

other, net 2,908 1,889 9,786 5,800

Interest expense (970) (1,071) (3,001) (3,943)

Gain on the sale of

business 18,808 -- 18,808 --

Total other income 20,746 818 25,593 1,857

Loss before noncontrolling

interest in Symphony

Evolution, Inc. (21,880) (30,743) (88,692) (91,144)

Loss attributed to

noncontrolling interest

in Symphony Evolution,

Inc. 8,184 5,546 22,233 14,834

Net loss $(13,696) $(25,197) $(66,459) $(76,310)

Net loss per share,

basic and

diluted $(0.14) $(0.30) $(0.68) $(0.91)

Shares used in computing

basic and diluted net

loss per share 98,551 84,178 97,313 83,972

EXELIXIS, INC.

CONSOLIDATED BALANCE SHEET DATA

(in thousands)

September 30, December 31,

2007 2006 (1)

(unaudited)

Cash and cash equivalents and short-term and

long-term marketable securities (2) $297,616 $263,180

Working capital $173,542 $150,814

Total assets $420,291 $395,417

St
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 ... Adult Stem Cell Technology Center, LLC ( ASCTC ) focused ... of adult tissue stem cells. His title “Asymmetric Self-Renewal ... the Future,” embodied the essence of his message to congress ...
(Date:12/24/2014)... On Friday, December 19, 2014, President Obama signed ... Appropriations Act of 2015, which for the first time, ... the Congressionally Directed Medical Research Programs (CDMRP) administered by ... working in conjunction with its allies on Capitol Hill, ...
(Date:12/24/2014)... 23, 2014 The report provides ... definition, classification, application and industry overview. This report ... cost structure. Production is separated by regions, technology ... materials, equipment, downstream client survey, marketing channels, industry ...
(Date:12/24/2014)... 24, 2014 The report expects global cell ... It also provides a carefully analyzed data about the vital ... , Full Copy of Report @ http://bit.ly/1yUxy0T , ... will keep witnessing growth at an impressive CAGR during near ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... ... Coverage, ... biopharmaceutical company focusing on the development of,novel, proprietary antibody-based products for ... developed,using BiTE(R) technology will be reported at the joint international,meeting of ...
... N.C., Oct. 23 Coordinating and timing,activities is ... the results of clinical trials. Marketers, who have ... trials,need to "worry about competitors stealing your thunder, ... was about," states one,interviewed executive. According to ...
... 22, 2007 In a major feat of nanotechnology ... with a wide-range of potential applications in chemistry, biology ... the device is capable of resolving the chemical composition ... with unprecedented detail. , Spearheaded by graduate students Nanfang ...
Cached Biology Technology:Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference 2Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference 3Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference 4Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference 5Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams 2Harvard University engineers demonstrate quantum cascade laser nanoantenna 2
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) has ... Watermarking and Fingerprinting Markets" report to their ... This insight provides an overview of ... Watermarking aims to control and monitor piracy by ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... ID Technology Now Embedded in a Fully Flexible ... ... Dec. 5 Fidelica Microsystems, Inc., a,pioneering developer of ... company,s FSC-3012 Biometrically,Authenticated Smart Card. This biometrically-authenticated credential,features a ...
... prices rise, the costs of lower-calorie foods are rising the ... the December issue of the Journal of the American Dietetic ... other low-calorie foods have jumped nearly 20 percent in the ... may be moving out of the reach of some American ...
... so that they will rethink how an object works ... using that object, according to a Yale study today ... Even when you add time pressure, or warn the ... unable to avoid reproducing the adults irrelevant actions, said ...
Cached Biology News:Fidelica Microsystems Announces Biometrically-Authenticated Smart Card 2Price of lower-calorie foods rising drastically, researchers find 2Humans appear hardwired to learn by 'over-imitation' 2
... anti-phospho-FAK (Ser843) ... acid region encompassing the human, mouse, ... Accession Number: NM_153831 ... Routinely evaluated by immunoblot. ...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Biology Products: